title: Akathisia and suicidal ideation in first-episode schizophrenia.
abstract: Patients with first-episode schizophrenia (FES) are known to be notably sensitive for developing extrapyramidal adverse effects, but the relation of akathisia and suicidal ideation has rarely been studied. The current report is an ongoing analysis of an 8-week double-blind randomized controlled multicenter trial in 289 FES, comparing risperidone and haloperidol. Assessments were conducted weekly and included the Hillside Akathisia Scale and 21-item Hamilton Depression Rating Scale ratings. Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol. The allocated treatment, anxiety, and nervousness had no influence. The present findings suggest a promoting effect of akathisia on suicidal ideation can not be ruled out in patients with FES.
authors.affiliation: Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany. fseemuel@med.lmu.de
authors.forename: Florian
authors.initials: F
authors.lastname: Seemüller
authors.forename: Rebecca
authors.initials: R
authors.lastname: Schennach
authors.forename: Andreas
authors.initials: A
authors.lastname: Mayr
authors.forename: Richard
authors.initials: R
authors.lastname: Musil
authors.forename: Markus
authors.initials: M
authors.lastname: Jäger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Maier
authors.forename: Stefan
authors.initials: S
authors.lastname: Klingenberg
authors.forename: Isabella
authors.initials: I
authors.lastname: Heuser
authors.forename: Joachim
authors.initials: J
authors.lastname: Klosterkötter
authors.forename: Markus
authors.initials: M
authors.lastname: Gastpar
authors.forename: Andrea
authors.initials: A
authors.lastname: Schmitt
authors.forename: Ralf
authors.initials: R
authors.lastname: Schlösser
authors.forename: Frank
authors.initials: F
authors.lastname: Schneider
authors.forename: Christian
authors.initials: C
authors.lastname: Ohmann
authors.forename: Ute
authors.initials: U
authors.lastname: Lewitzka
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Gaebel
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
authors.forename: Michael
authors.initials: M
authors.lastname: Riedel
mesh_terms: D000328:Adult; D000367:Age Factors; D017109:Akathisia, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000150:complications; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects; D011569:Psychiatric Status Rating Scales; D011595:Psychomotor Agitation / Q000453:epidemiology / Q000209:etiology; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D059020:Suicidal Ideation; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D011433:Propranolol; D006220:Haloperidol; D018967:Risperidone